Glucocorticoids and cancer

Advances in Experimental Medicine and Biology

Volumn 872, Issue , 2015, Pages 315-333

  Pufall, Miles A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Apoptosis; Chemotherapy; Leukemia; Lymphoma; Palliative

Indexed keywords

ANDROGEN RECEPTOR; ASPARAGINASE; ASPARAGINASE MACROGOL; BLEOMYCIN; BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CHLORAMBUCIL; CORTICOTROPIN; CORTISONE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLERGIC REACTION; ARTICLE; AVASCULAR NECROSIS; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LEUKEMIA REMISSION; LYMPHOMA; LYMPHOSARCOMA; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MULTIPLE MYELOMA; MUSCLE ATROPHY; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RASH; T CELL LEUKEMIA; TREATMENT OUTCOME; HEMATOLOGIC DISEASE; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

GLUCOCORTICOIDS; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; RECEPTORS, GLUCOCORTICOID;

EID: 84938365425     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2895-8_14     Document Type: Article

References (87)

1. Kendall EC. Hormones. Annu Rev Biochem. 1941;10:285-336.
2. Dougherty TF, White A. Effect of pituitary adrenotropic hormone on lymphoid tissue. Exp Biol Med. 1943;53(2):132-3. doi: 10.3181/00379727-53-14219P.
3. Heilman FR, Kendall EC. The influence of 11-dehydr0-17-hydroxycorticosterone (compound E) on the growth of a malignant tumor in the Mouse1. Endocrinology. 1944;34(6):416-20.
4. Murphy JB, Sturm E. The effect of adrenal cortical and pituitary adrenotropic hormones on transplanted leukemia in rats. Science. 1944;99(2572):303. doi: 10.1126/science.99.2572.303.
5. Pearson OH, Eliel LP, Rawson RW, Dobriner K, Rhoads CP. Acth- and cortisone-induced regression of lymphoid tumors in man. A preliminary report. Cancer. 1949;2(6):943-5. doi: 10.1002/1097-0142(194911)2:6<943::AID-CNCR2820020602>3.0.CO;2-P.
6. Pearson OH, Eliel LP. Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. J Am Med Assoc. 1950;144(16):1349-53.
7. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-53. doi: 10.1158/0008-5472.CAN-07-6611.
8. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. J Exp Med. 1963;118:121-48.
9. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78. doi: 10.1056/NEJMra052603.
10. Dördelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94(4):1209-17.
11. Lonnerholm G, Thorn I, Sundstrom C, et al. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia. Leuk Res. 2009;33(1):46-53. doi: 10.1016/j.leukres.2008.06.012.
12. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood. 1997;89(8):2959-65.
13. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90(7):2723-9.
14. Inaba H, Pui C-H. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096-106. doi: 10.1016/S1470-2045(10)70114-5.
15. Teuffel O, Kuster SP, Hunger SP, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011;25(8):1232-8. doi: 10.1038/leu.2011.84.
16. Mittelstadt PR, Monteiro JP, Ashwell JD. Thymocyte responsiveness to endogenous glucocorticoids is required for immunological fitness. J Clin Invest. 2012;122(7):2384-94. doi: 10.1172/ JCI63067.
17. Gruver-Yates AL, Quinn MA, Cidlowski JA. Analysis of glucocorticoid receptors and their apoptotic response to dexamethasone in male murine B cells during development. Endocrinology. 2014;155(2):463-74. doi: 10.1210/en.2013-1473.
18. Smith LK, Cidlowski JA. Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. Prog Brain Res. 2010;182:1-30. doi: 10.1016/S0079-6123(10)82001-1.
19. Ploner C, Schmidt S, Presul E, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Biol. 2005;93(2-5):153-60. doi: 10.1016/j.jsbmb.2004.12.017.
20. Lambrou GI, Vlahopoulos S, Papathanasiou C, et al. Prednisolone exerts late mitogenic and biphasic effects on resistant acute lymphoblastic leukemia cells: relation to early gene expression. Leuk Res. 2009;33(12):1684-95. doi: 10.1016/j.leukres.2009.04.018.
21. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010;120(4):1310-23. doi: 10.1172/JCI39987DS1.
22. Ploner C, Rainer J, Niederegger H, et al. The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia. Leukemia. 2007;22(2):370-7. doi: 10.1038/sj.leu.2405039.
23. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11:S45-55. doi: 10.1038/sj.cdd.4401456.
24. Tissing WJE, den Boer ML, Meijerink JPP, et al. Genomewide identification of prednisoloneresponsive genes in acute lymphoblastic leukemia cells. Blood. 2007;109(9):3929-35. doi: 10.1182/blood-2006-11-056366.
25. Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E. Chapter 6 mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv Cancer Res. 2008;101:127-248. doi: 10.1016/S0065-230X(08)00406-5.
26. Schmidt S. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood. 2006;107(5):2061-9. doi: 10.1182/blood-2005-07-2853.
27. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351(6):533-42. doi: 10.1056/NEJMoa033513.
28. Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006; 10(4):331-42. doi: 10.1016/j.ccr.2006.09.006.
29. Bachmann PS. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood. 2005;105(6):2519-26. doi: 10.1182/blood-2004-05-2023.
30. Cario G, Fetz A, Bretscher C, et al. Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia. Ann Hematol. 2008;87(9):709-16. doi: 10.1007/s00277-008-0504-x.
31. Hulleman E, Kazemier KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009;113(9):2014-21. doi: 10.1182/blood-2008-05-157842.
32. Buentke E, Nordström A, Lin H, et al. Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. Blood Cancer J. 2011;1(7):e31-9. doi: 10.1038/bcj.2011.27.
33. Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood. 1993;81(9):2386-93.
34. Briggs SD, Bryk M, Strahl BD, et al. Histone H3 lysine 4 methylation is mediated by Set1 and required for cell growth and rDNA silencing in Saccharomyces cerevisiae. Genes Dev. 2001;15(24):3286-95. doi: 10.1101/gad.940201.
35. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10(5):1107-17.
36. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stemcell development. Nat Rev Cancer. 2007;7(11):823-33. doi: 10.1038/nrc2253.
37. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377-80. doi: 10.1126/science.1164266.
38. Piovan E, Yu J, Tosello V, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 2013;24(6):766-76. doi: 10.1016/j.ccr.2013.10.022.
39. Galliher-Beckley AJ, Williams JG, Cidlowski JA. Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol. 2011;31(23):4663-75. doi: 10.1128/MCB.05866-11.
40. Gruber G, Carlet M, Türtscher E, et al. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia. 2009; 23(4):820-3. doi: 10.1038/leu.2008.360.
41. Schmidt S, Irving JAE, Minto L, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J. 2006;20(14):2600-2. doi: 10.1096/fj.06-6214fje.
42. Wu I, Shin SC, Cao Y, et al. Selective glucocorticoid receptor translational isoforms reveal glucocorticoid-induced apoptotic transcriptomes. Cell Death Dis. 2013;4, e453. doi: 10.1038/ cddis.2012.193.
43. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology, vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
44. Thomas DA. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104(6):1624-30. doi: 10.1182/blood-2003-12-4428.
45. Real PJ, Tosello V, Palomero T, et al. γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2008;15(1):50-8. doi: 10.1038/nm.1900.
46. Rajkumar SV. Multiple myeloma. Curr Probl Cancer. 2009;33(1):7-64. doi: 10.1016/j. currproblcancer.2009.01.001.
47. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-72. doi: 10.1182/ blood-2007-10-078022.
48. Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013;19(13):3337-44. doi: 10.1158/1078-0432.CCR-12-1881.
49. Grugan KD, Ma C, Singhal S, Krett NL, Rosen ST. Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma. J Steroid Biochem Mol Biol. 2008;110(3-5):244-54. doi: 10.1016/j. jsbmb.2007.11.003.
50. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324-39. doi: 10.1016/S0140-6736(09)60221-X.
51. Viviani S, Zinzani PL, Rambaldi A. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203-12. doi: 10.1056/ NEJMoa1100340.
52. Rosenthal MC, Saunders RH, Schwartz LI, Zannos L, Perez Santiago E, Dameshek W. The use of adrenocorticotropic hormone and cortisone in the treatment of leukemia and leukosarcoma. Blood. 1951;6(9):804-23.
53. Smolej L. The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2012;21(7):1009-17. doi: 10.1517/13543784.2012.690393.
54. Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013;121(9):1501-9. doi: 10.1182/blood-2012-08-452607.
55. Connors JM. Non-Hodgkin lymphoma: the clinician's perspective-a view from the receiving end. Mod Pathol. 2013;26(s1):S111-8. doi: 10.1038/modpathol.2012.184.
56. Kassi E, Moutsatsou P. Glucocorticoid receptor signaling and prostate cancer. Cancer Lett. 2011;302(1):1-10. doi: 10.1016/j.canlet.2010.10.020.
57. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New agents for prostate cancer. Ann Oncol. 2014;25(9):1700-9. doi: 10.1093/annonc/mdu038.
58. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013;190(2):429-38. doi: 10.1016/j.juro.2013.05.005.
59. Montgomery B, Mostaghel E, Cheng H, Drechsler J. Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl. 2014;16(3):354-8. doi: 10.4103/1008-682X.125392.
60. Yemelyanov A, Czwornog J, Chebotaev D, et al. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene. 2006;26(13):1885-96. doi: 10.1038/sj.onc.1209991.
61. Cavarretta IT, Neuwirt H, Untergasser G, et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene. 2006;26(20):2822-32. doi: 10.1038/sj.onc.1210097.
62. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309-22. doi: 10.1016/j. cell.2013.11.012.
63. Zhong DT, Shi CM, Chen Q, Huang JZ, Liang JG, Lin D. Etoposide, vincristine, doxorubicin and dexamethasone (EVAD) combination chemotherapy as second-line treatment for advanced AIDS-related Kaposi's sarcoma. J Cancer Res Clin Oncol. 2011;138(3):425-30. doi: 10.1007/ s00432-011-1109-7.
64. Sweeney CJ. Phase II, study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24(21):3451-7. doi: 10.1200/JCO.2005.03.6699.
65. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-51. doi: 10.1200/ JCO.2007.15.0375.
66. Hanna N. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-97. doi: 10.1200/JCO.2004.08.163.
67. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007;25(30):4743-50. doi: 10.1200/JCO.2007.12.3026.
68. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(3):468-73. doi: 10.1200/JCO.2007.13.1912.
69. Vogelzang NJ. Phase III, study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44. doi: 10.1200/JCO.2003.11.136.
70. Ceresoli GL, Phase II. Study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443-8. doi: 10.1200/JCO.2005.04.3190.
71. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999;17(6):1876-83.
72. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407-14. doi: 10.1200/JCO.2006.09.3849.
73. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25(23):3415-20. doi: 10.1200/ JCO.2006.09.7535.
74. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25(23):3399-406. doi: 10.1200/JCO.2006.08.9102.
75. American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24(18):2932-47. doi: 10.1200/JCO.2006.06.9591.
76. Aapro MS, Alberts DS. Dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med. 1981;305(9):520.
77. Rich WM, Abdulhayoglu G, DiSaia PJ. Methylprednisolone as an antiemetic during cancer chemotherapy-a pilot study. Gynecol Oncol. 1980;9(2):193-8.
78. Chu C-C, Hsing C-H, Shieh J-P, Chien C-C, Ho C-M, Wang J-J. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol. 2014;722(C):48-54. doi: 10.1016/j.ejphar.2013.10.008.
79. Hursti TJ, Fredrikson M, Steineck G, Börjeson S, Fürst CJ, Peterson C. Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids. Br J Cancer. 1993;68(1):112-4.
80. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-23. doi: 10.1056/NEJMra050541.
81. Mantovani G, Maccio A, Massa E, Lai P, Esu S. Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect. Oncol Rep. 1997;4(5):1051-3.
82. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52(2):72-91.
83. Quax RAM, Peeters RP, Feelders RA. Selective glucocorticoid receptor modulators: future of glucocorticoid immunosuppressive therapy? Endocrinology. 2011;152(8):2927-9. doi: 10.1210/en.2011-1258.
84. Clark AR, Belvisi MG. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther. 2012;134(1):54-67. doi: 10.1016/j.pharmthera.2011.12.004.
85. Jing D, Bhadri VA, Beck D, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid- induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood. 2014;125(2):273-83. doi: 10.1182/blood-2014-05-576470.
86. Moutsatsou P, Kassi E, Papavassiliou AG. Glucocorticoid receptor signaling in bone cells. Trends Mol Med. 2012;18(6):348-59. doi: 10.1016/j.molmed.2012.04.005.
87. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002;108(4):465-74.